JP2006518589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518589A5 JP2006518589A5 JP2005501293A JP2005501293A JP2006518589A5 JP 2006518589 A5 JP2006518589 A5 JP 2006518589A5 JP 2005501293 A JP2005501293 A JP 2005501293A JP 2005501293 A JP2005501293 A JP 2005501293A JP 2006518589 A5 JP2006518589 A5 JP 2006518589A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- protein
- promoter
- nucleic acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 102
- 108090000623 proteins and genes Proteins 0.000 claims 68
- 102000004169 proteins and genes Human genes 0.000 claims 65
- 150000007523 nucleic acids Chemical class 0.000 claims 41
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 230000010076 replication Effects 0.000 claims 19
- 101710199711 Early E1A protein Proteins 0.000 claims 13
- 239000013598 vector Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000022131 cell cycle Effects 0.000 claims 3
- 230000006037 cell lysis Effects 0.000 claims 3
- 239000000824 cytostatic agent Substances 0.000 claims 3
- 230000002074 deregulated effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000003362 replicative effect Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 241000700198 Cavia Species 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 241001494479 Pecora Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005616 epidermal appendage tumor Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000023974 pharynx neoplasm Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 201000008753 synovium neoplasm Diseases 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10248039 | 2002-10-15 | ||
| DE10248039.7 | 2002-10-15 | ||
| DE10322530 | 2003-05-19 | ||
| DE10322530.7 | 2003-05-19 | ||
| PCT/EP2003/005583 WO2003099859A2 (de) | 2002-05-27 | 2003-05-27 | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
| DE10324085.3 | 2003-05-27 | ||
| DE10324085 | 2003-05-27 | ||
| EPPCT/EP03/05583 | 2003-05-27 | ||
| PCT/EP2003/011427 WO2004035616A2 (de) | 2002-10-15 | 2003-10-15 | Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006518589A JP2006518589A (ja) | 2006-08-17 |
| JP2006518589A5 true JP2006518589A5 (https=) | 2006-11-24 |
| JP4988199B2 JP4988199B2 (ja) | 2012-08-01 |
Family
ID=34317534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501293A Expired - Lifetime JP4988199B2 (ja) | 2002-10-15 | 2003-10-15 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP4988199B2 (https=) |
| KR (1) | KR101123510B1 (https=) |
| AU (1) | AU2003271730A1 (https=) |
| CA (1) | CA2515650C (https=) |
| RU (1) | RU2393221C2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487811A1 (en) | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
| EP1689445B1 (de) | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| EP1689446B1 (de) * | 2003-11-14 | 2015-01-07 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| EP1830864A2 (de) * | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| JP5584393B2 (ja) | 2004-12-31 | 2014-09-03 | ホルム，ペル・ゾンネ | 動物細胞における多剤耐性を逆転させる方法 |
| RU2561050C2 (ru) * | 2013-08-28 | 2015-08-20 | Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера |
| CA2925487C (en) * | 2013-09-24 | 2023-11-07 | University Of Washington Through Its Center For Commercialization | Desmoglein 2 (dsg2) binding proteins and uses therefore in treating disorders associated with epithelial tissues |
| CA3092907A1 (en) * | 2018-03-05 | 2019-09-12 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
| EP3822355A4 (en) * | 2018-07-10 | 2022-05-18 | Genemedicine Co., Ltd. | ANTITUMOR COMPOSITION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199568T1 (de) * | 1993-02-16 | 2001-03-15 | Onyx Pharma Inc | Cytopatische viren zur therapie und prophylaxe der neoplasie |
| US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| US6100086A (en) * | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
| DE10015413A1 (de) * | 2000-03-23 | 2001-09-27 | Max Delbrueck Centrum | Mittel zur Diagnose und Therapie viraler Erkrankungen |
| ES2287181T3 (es) * | 2000-12-28 | 2007-12-16 | Per Sonne Holm | Sistemas adenovirales y sus aplicaciones. |
-
2003
- 2003-10-15 RU RU2005114516/13A patent/RU2393221C2/ru active
- 2003-10-15 AU AU2003271730A patent/AU2003271730A1/en not_active Abandoned
- 2003-10-15 CA CA2515650A patent/CA2515650C/en not_active Expired - Fee Related
- 2003-10-15 KR KR1020057006313A patent/KR101123510B1/ko not_active Expired - Fee Related
- 2003-10-15 JP JP2005501293A patent/JP4988199B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511212A5 (https=) | ||
| Gao et al. | Injectable immunotherapeutic hydrogel containing RNA-loaded lipid nanoparticles reshapes tumor microenvironment for pancreatic cancer therapy | |
| Oduk et al. | VEGF nanoparticles repair the heart after myocardial infarction | |
| ES2256842T3 (es) | Vector de adenovirus recombinante y metodos de uso. | |
| Zhu et al. | Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo | |
| Matsuda et al. | Hypoxia-inducible factor-1 α DNA induced angiogenesis in a rat cerebral ischemia model | |
| Spitzweg et al. | The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment | |
| Fan et al. | A multifunction lipid-based CRISPR-Cas13a genetic circuit delivery system for bladder cancer gene therapy | |
| JP2007511507A (ja) | 癌を処置するための治療レジメン | |
| CN100506284C (zh) | 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法 | |
| JP2005536447A (ja) | Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置 | |
| JP2006518589A5 (https=) | ||
| JP2006512284A5 (https=) | ||
| JP2008526188A5 (https=) | ||
| Dash et al. | Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic | |
| Ohashi et al. | In vivo adenovirus‐mediated prodrug gene therapy for carcinoembryonic antigen‐producing pancreatic cancer | |
| Srivastava et al. | Advancement in magnetic hyperthermia-based targeted therapy for cancer treatment | |
| Cordier Kellerman et al. | Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma | |
| JP2002524036A (ja) | 抗血管形成プラスミドおよび送達システムならびにその作製および使用方法 | |
| JP2002523032A (ja) | 遺伝子の発現の増強および制限方法 | |
| RU2005114516A (ru) | Аденовирус с обращенной генной экспрессией и его применение | |
| Matsumoto et al. | Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo | |
| Gupta et al. | Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model | |
| Liu et al. | Nanotargeted cationic lipid microbubbles carrying HSV‐TK gene inhibit the development of subcutaneous liver tumor model after HIFU ablation | |
| Sonabend et al. | Oncolytic adenoviral therapy for glioblastoma multiforme |